Leucine-rich alpha-2 glycoprotein as a superior biomarker to C-reactive protein for detecting small bowel lesions in Crohn’s disease

Table 1 Overall characteristics of the study participants, n (%)

Variables	n = 133
Sex, male	103 (77.4)
Age, median years (IQR)	38 (28-48.5)
BMI, median years (IQR)	20.9 (19.25-24.25)
Period between endoscopy and LRG measurement, median days (IQR)	18 (3-40)
Location
L1: Ileal	43 (32.3)
L2: Colonic	10 (7.5)
L3: Ileocolonic	80 (60.2)
Behavior
B1: Inflammatory	51 (38.3)
B2: Stricturing	54 (40.6)
B3: Penetrating	28 (21.0)
Previous intestinal resection	42 (31.6)
Concomitant treatment
5-Aminosalicylic acid	70 (52.6)
Steroids	1 (0.8)
Immunomodulator	34 (25.5)
Biologics	96 (72.2)
Anti-TNF alpha	44 (33.1)
Anti-integrin	4 (3.0)
Anti-interleukin 12/23 p40	40 (30.1)
Anti-interleukin 23 p19	6 (4.5)
JAK inhibitor	1 (0.8)
LRG, median μg/mL (IQR)	12.5 (9.4-18.0)
CRP, median mg/dL (IQR)	0.1 (0.03-0.26)
Albumin, g/dL (IQR)	4.2 (3.9-4.5)
HBI (IQR)	0 (0-2)
mSES-CD in the ileum (IQR)	3 (0-4)
mSES-CD in the colon (IQR)	0 (0-3)

IQR: Interquartile range; BMI: Body mass index; TNF: Tumor necrosis factor; JAK: Janus kinase; LRG: Leucine-rich alpha-2 glycoprotein; CRP: C-reactive protein; HBI: Harvey-Bradshaw index; mSES-CD: Modified simple endoscopic score for Crohn’s disease.